Squamous Cell Lung Cancer Clinical Trial
Official title:
A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG
Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether surgery is more effective with or without chemotherapy for non-small cell lung cancer.
PRIMARY OBJECTIVES:
I. To determine if adjuvant chemotherapy can favorably alter the prognosis of the subgroup
of resected stage I patients who, following complete surgical resection of their disease,
are defined as "high risk" based on the presence of a T2N0 tumor (according to the criteria
of the International Staging System for lung cancer).
SECONDARY OBJECTIVES:
I To compare failure-free survival of patients with T2N0 stage I NSCLC who have and have not
been treated with adjuvant chemotherapy.
II. To determine the toxicities associated with adjuvant chemotherapy. III. To describe the
pattern of disease recurrence.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor
histology (squamous cell vs nonsquamous cell), degree of differentiation (poorly
differentiated vs other), and mediastinal node sampling at surgery (yes vs no). Within 4-8
weeks after surgery, patients are randomized to 1 of 2 treatment arms.
Arm I:Patients receive no further therapy.
Arm II: Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by
carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
Patients are followed every 4 months for 2 years and then every 6 months thereafter.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Withdrawn |
NCT03346304 -
Photodynamic Therapy for the Prevention of Lung Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02288026 -
Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
|
N/A | |
| Terminated |
NCT01491633 -
Dasatinib in Advanced Squamous Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00087412 -
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00049543 -
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
| Recruiting |
NCT02787473 -
A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00387374 -
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
|
Phase 2 | |
| Recruiting |
NCT05550961 -
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
|
||
| Recruiting |
NCT05292859 -
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
|
||
| Recruiting |
NCT05607108 -
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03574818 -
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
|
Phase 2 | |
| Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 | |
| Completed |
NCT00040794 -
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00042835 -
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT03827850 -
FGFR Inhibitor in FGFR Dysregulated Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01345851 -
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
|
N/A | |
| Withdrawn |
NCT02059967 -
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
|
Phase 1 | |
| Completed |
NCT01082549 -
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
|
Phase 3 |